The Benefit of Benralizumab Monoclonal Antibody Treatment for Severe Eosinophilic Asthma in a Case Series (Pulmonology Clinic Târgu Mureș, Romania)

Publié en ligne: 14 oct. 2021

Pages: 157 - 161

Reçu: 04 sept. 2021

Accepté: 11 sept. 2021

DOI: https://doi.org/10.2478/jim-2021-0030

Mots clés

monoclonal antibody therapy, severe eosinophilic asthma, clinical parameters, eosinophils

© 2021 Nimród László et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.